Business Context and Reporting Period
Company: Teva Pharmaceutical Industries Limited
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Teva is a biopharmaceutical company enabled by a generics business, operating through three primary segments: United States, Europe, and International Markets. The company is executing its "Pivot to Growth" strategy, focusing on innovative medicines, biosimilars, and portfolio optimization. In Q1 2026, the company reclassified its U.S. distribution business (Anda) from the United States segment to "Other Activities."
Key Financial Metrics
| Metric (in millions USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenues | $3,982 | $3,891 |
| Gross Profit | $1,972 | $1,877 |
| Gross Margin | 49.5% | 48.2% |
| Operating Income | $652 | $519 |
| Net Income (Attributable to Teva) | $369 | $214 |
| Diluted EPS | $0.31 | $0.18 |
| Operating Cash Flow | ($40) | ($105) |
| Free Cash Flow | $188 | $107 |
| Total Debt | $16,627 | $16,807 |
| Cash and Cash Equivalents | $3,741 | $1,697 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 2% year-over-year (USD) but decreased 3% in local currency terms. The decline in local currency was driven by lower generic product revenues (notably lenalidomide capsules) and the divestment of the Japan business venture, partially offset by strong growth in innovative products like AUSTEDO.
- Profitability: Operating income rose 26% to $652 million, primarily due to a significant reduction in intangible asset impairments ($8 million in Q1 2026 vs. $121 million in Q1 2025) and higher gross profit.
- Segment Performance:
- United States: Revenues were flat ($1.534 billion); segment profit decreased 2% to $507 million due to higher selling and marketing expenses.
- Europe: Revenues increased 12% in USD ($1.340 billion); segment profit surged 22% to $401 million.
- International Markets: Revenues decreased 10% in USD ($524 million); segment profit fell 33% to $65 million, largely due to the Japan divestment.
- Debt and Liquidity: Total debt decreased slightly to $16.6 billion. Cash and cash equivalents increased significantly to $3.7 billion, supported by improved operating cash flow dynamics and securitization activities.
Guidance, Outlook, Risks, and Unusual Items
- Strategic Acquisitions: In April 2026, Teva agreed to acquire Emalex Biosciences for $700 million (plus milestones) to add ecopipam (Tourette syndrome treatment) to its pipeline. Closing is expected in Q3 2026.
- Restructuring: The company recorded $25 million in restructuring expenses, primarily related to headcount reductions under its Transformation programs, aiming to reduce the workforce by approximately 8% by the end of 2027.
- Legal Contingencies:
- Opioids: Teva recorded $72 million in legal settlements and loss contingencies, mainly related to the nationwide opioid settlement agreement. Estimated cash payments for 2026 are $379 million.
- Antitrust: Ongoing proceedings include a European Commission fine of €462.6 million regarding COPAXONE (appealed) and various U.S. antitrust cases regarding generic drug pricing and market allocation.
- Geopolitical Risks: The filing highlights risks from ongoing conflicts in the Middle East (Iran) and between Russia and Ukraine, which could disrupt supply chains and logistics, though the impact on Q1 2026 results was deemed immaterial.
- Regulatory Environment: Risks include the impact of the "One Big Beautiful Bill" (OBBBA) signed in July 2025, which may reduce Medicaid enrollment and alter pricing leverage, as well as U.S. Executive Orders on drug pricing.
Key Facts for Investor Verification
- Revenue Mix Shift: Verify the sustainability of revenue growth from innovative products (AUSTEDO, AJOVY) as generic revenues (Revlimid) continue to face competition.
- Impairment Volatility: Confirm that the $113 million reduction in intangible asset impairments compared to Q1 2025 is a one-time benefit rather than a trend, as future impairments remain a risk.
- Debt Covenants: Monitor compliance with the $1.8 billion Revolving Credit Facility (RCF) leverage ratio covenant (max 4.25x), especially given the company's significant debt load.
- Opioid Settlement Payments: Track the $379 million in scheduled opioid settlement payments for 2026 and the potential for additional liabilities from pending third-party payer settlements.
- API Divestiture: Assess the progress and valuation of the planned divestiture of the API business, currently classified as "held for sale."